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A B S T R A C T
Controversy exists as to whether the deletion/deletion (DD) genotype of angiotensin l-converting enzyme (ACE) gene
polymorphism is associated with coronary heart disease (CHD). There are only a few studies dealing with this issue in
the elderly, also with controversial results. The aim of this study was the assessment of correlation between genetic mark-
ers and the risk of CHD in the elderly. The results indicated DD genotype importance for CHD in the elderly as proven by
discriminant analysis (c2=25,77; df=16; p=0.0620). However, the use of univariate method demonstrated no correlation
between DD genotype of ACE gene polymorphism and coronary artery disease. D allele of ACE gene was associated with
higher activities of ACE plasma. A weak, but increased risk of MI is associated with high frequency of DD genotype in the
elderly. Strong correlation between ACE polymorphism and ACE plasma activities was demonstrated.
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Introduction
Although smoking, hypertension, diabetes mellitus,
obesity and dyslipidemia are well known risk factors for
CHD, many patients without any of these classical risk
factors develop MI1. This is particularly the case at an ad-
vanced age2. It is very well known that the general popu-
lation is getting older and that cardiovascular mortality
and morbidity increase with age. Therefore, it is very im-
portant to identify all risk factors, including genetic
markers, in order to reduce mortality and morbidity of
CHD in the entire population, particularly in the elderly.
Several genetic investigations, such as case-control stu-
dy, affected sib-pair analyses, and rat-cross-examinations
have attempted to elucidate the genetic pathogenesis of
CHD. An insertion /deletion (ID) polymorphism identi-
fied in 1990 by Rigat et al.3, with the insertion or deletion
of a 2-base pair fragment in the 17q23 chromosome, is as-
sociated with the ACE plasma and cellular activity. Al-
though the presence of the D allele of ACE gene is associ-
ated with increased plasma ACE activities4, which is a
rate-limiting enzyme in the renin angiotensin system,
the risk for CHD was not consistent. Some investigators
suggested that deletion polymorphism in the gene encod-
ing ACE might have a stronger association with CHD
than the ID polymorphism5. The DD genotype appears to
be an independent risk factor not only for myocardial in-
farction (MI)6, but also for left ventricular hypertrophy7,
ischaemic or dilated cardiomyopathy8, family history of
sudden cardiac death9, ischaemic cerebrovascular disea-
se10 and chronic heart failure11,12. The Framingham stu-
dy13 revealed that the homozygotus deletion polymor-
phism of the angiotensin-converting enzyme gene (ACE
DD) was associated with increased risk for the hyper-
tensic white male. A few years later this correlation was
also confirmed in the Japanese14. However, some other
studies did not find any strong correlation between the
polymorphism of ACE genotype and MI or CHD15,16
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The objective of this study was to test the following
hypothesis: if specific ACE genetic polymorphism (DD
genotype) is related to cardiovascular mortality, then a
decreased frequency of »at risk« alleles and an increased
frequency of »protective« allele should be present in the
elderly, thus affecting their survival outcome. We also
wanted to prove whether there was any correlation be-
tween insertion /deletion polymorphism of ACE genotype
and ACE activity level.
Methods
Study Population
The study group consisted of all patients from one GP
outpatient office, Kalinovica in Zagreb, Croatia, older
than 65 years. All 346 patients (230 women and 116 men)
were retired and had spent almost their whole life in
Zagreb. After a thorough clinical examination of patients
and patients’ records at the beginning of the study, labo-
ratory analyses and ECGs were done. The study com-
plied with the Helsinki Declaration. All subjects received
oral and written information about the study prior to
giving written informed consent.
Measurements
Basic clinical variables included age, gender, BMI
(body mass index), smoking habits, total cholesterol (TC),
triglycerides, HDL-C, LDL-C, apo A I, apo B, apo E, fast-
ing glucose, fibrinogen, uric acid, systolic (SBP) and dia-
stolic blood pressure (DBP).
After >10 minutes of rest, SBP and DBP were mea-
sured twice by the same physician. Hypertension was de-
fined as the mean SBP of ³140 mmHg or the mean DBP
of ³90 mmHg. Patients currently under antihypertensive
medication were, regardless of SBP and DBP levels, also
taken into account.
All blood samples were taken after a 12–14 h over-
night fast. Venous blood was drawn into evacuated blo-
od-collection tubes without anticoagulant. After clotting,
each specimen was centrifuged at 1200x g for 20 min and
stored at 4 °C until analysis. Samples were analysed the
following day. The serum concentrations of cholesterol
and triglycerides were measured by standard enzymatic
methods (CHOD-PAP and GPO-PAP, respectively) using
commercial kits. The serum concentration of HDL-C was
measured after precipitation with dextran sulphate and
magnesium chloride, while the serum concentration of
LDL-C was estimated using Friedewald’s formula. Apo-
proteins AI, B and E were measured by radial immuno-
diffusion.
Determination of Genotype
The presence (allele I) or absence (allele D) of the 287
bp Alu repeat in intron 16 of the ACE gene were deter-
mined by evaluating the size of DNA fragments after
PCR amplification, using the primers and PCR condi-
tions as described by Rigat et al.3. ID polymorphism was
determined by agarose gel electrophoresis with ethidium
bromide staining, and DD genotype was reconfirmed by
insertion of allele-specific amplification according to Lind-
painter’s protocol with minor modification.
Clinical events
Diagnosis of coronary heart disease diagnosis was
based on the hospital discharge summary containing ei-
ther the cardiologist’s medical records or pathological Q
wave in the ECG. In every patient with suspect ECG and
no available data on hospital or any other treatment for
CHD or myocardial infarction, a vectocardiogram was
performed to confirm the diagnosis. Patients with PTCA
or coronary artery by-pass without any myocardial in-
farction or existing angina pectoris were also considered
as CHD patients.
Statistical analysis
The difference in genotypes or allele distribution be-
tween the patients with and those without CHD was ex-
amined using c2 test. The significance level was set at
p<0.05. The correlation between ACE gene polymor-
phism and CHD was analysed by discriminant analysis.
The statistical analysis was performed with SPSS 9.0
software (SPSS Inc., Chicago, IL, USA, 1999).
Results
Patient characteristics
The analysis of data from 346 subjects showed that 90
(60 females and 30 males) had CHD, while 256 subjects
had no signs of CHD. Among those with CHD, 27 had MI
(12 inferior, 3 posterior, 3 inferoposterior, 5 anteroseptal,
1 lateral, 3 anterior, 1 anterolateral and 1 high lateral).
Thirty-five patients had angina, 19 of them were without
previous MI and 16 had angina as a late complication of
MI. Twenty-six subjects had pathologic Q wave in ECG,
but 6 of them were unaware that they had survived MI.
Therefore, a vectocardiogram was performed which pro-
ved chronic sequellae of the MI. One patient had PTCA
without MI, angina or pathologic Q wave.
Genotype distribution of ACE gene polymorphism
From 346 examinees, for full and qualitative analyses
of genome, 322 samples (214 female and 108 male) were
accessible.
The distribution of DD, ID and II genotype was
35.4%, 48.1% and 16.4%, respectively. Statistically signif-
icant correlation between ACE gene polymorphism and
CHD was not demonstrated for the entire group either in
males or females analysed separately.
Relative predictive value of quantitatively measured
ACE gene polymorphism and other risk factors (fasting
sugar, TC, triglycerides, HDL-C LDL-C, uric acid, apo
A-l, apo B, apo E, systolic and diastolic blood pressure
and cigarette smoking) for CHD was also estimated by
discriminant analysis.
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Results indicated DD genotype importance for the de-
velopment of CHD at an older age. The obtained dis-
criminant function was not statistically significant at the
conventional level of significance (c2=25.77; df=16;
p=0.0620). Since it was significant at 7% level, it might
be described as exploratory. Table 2 shows the structure
matrix for the obtained discriminant function. Discri-
minant function was defined by five variables (uric acid,
fibrinogen, polymorphism ACE gene (DD genotype), ACE
activity level, and Apo E).
Centroid of compared groups on discriminant func-
tion is shown in Table 3.
In the observed group classified as diseased (n=90),
with determined risk factors for CHD, 60.0% were esti-
mated as diseased, and 40.0% as healthy due to the exis-
tence of unknown risk factors by which the »healthy«
group was determined within the diseased group. In the
other group classified as healthy (n=256), 37.5% were es-
timated as diseased and 62.5% as healthy because CHD
had not yet developed despite the existing risk factors.
On the basis of the Centroid and according to Tale 2
»healthy« differ from »diseased« with higher values of uric
acid and higher values of ACE activity, and lower values of
fibrinogen, II genotype and lower values of Apo E. Sub-
jects were classified with 61.85% of accuracy (Table 4).
Reverse correlation of DD genotype and ACE activity
level related to CHD was revealed by discriminant analy-
sis. The comparison of ACE activity level and DD geno-
type distributions within genders and in the entire group
was performed by univariate analysis (Table 5).
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TABLE 1
ANGIOENSIN CONVERTING ENZYME (ACE) GENE POLYMORPHISM AND CORONARY HEART DISEASE (CHD) IN THE ELDERLY
ACE
Genotype
Gender
CHD
(Number of examinees) Total
Yes p* No
DD Total
n=322
28 0.18724 86 114
ID 41 114 155
II 20 33 53
DD Female
n=214
17 0.24014 49 66
ID 27 82 109
II 15 24 39
DD Male
n=108
11 0.55799 37 48
ID 14 32 46
II 5 9 14
*p<0.05
TABLE 2
STRUCTURE MATRIX OF DISCRIMINANT FUNCTION
Variable Discriminant function
Uric acid –0.67655
Fibrinogen 0.37037
DD genotype 0.34958
Angiotensin converting enzyme
(ACE) activity level
–0.28986
Apoprotein E (Apo E) 0.26907
TABLE 3
CENTROID OF COMPARED GROUPS ON THE DISCRIMINANT
FUNCTION
Under observation Discriminant function
Diseased –0.47188
Healthy 0.16590
TABLE 4
RESULTS OF CLASSIFICATION
Under
observation
Estimated classification in the group
Diseased Healthy
Diseased
n=90
54
60.0%
36
40.0%
Healthy
n=256
96
37.5%
160
62.5%
TABLE 5
ANGIOTENSIN CONVERTING ENZYME (ACE) GENE POLYMOR-
PHISM AND ACE ACTIVITY LEVEL IN THE ELDERLY
ACE
(U/L)
Gender
ACE Genotype (n)
Total p*
DD ID II
8–52 Total 89 132 50 271
³ 52 n=322 25 23 3 51 0.02462
8–52 Female 52 91 38 181
³ 52 n=214 14 18 1 33 0.03440
8–52 Male 37 41 14 108
³ 52 n=108 11 5 2 18 0.28363
*p<0.05
Statistically significant correlation between plasma
ACE activity levels and DD genotype was found for the
entire group (p=0.02462) and also for female (p=0.03440)
although not for male patients.
Discussion
Although 'classical’ risk factors for CHD are well
known, many patients without any of these risk factors
develop myocardial infarction, particularly at an advan-
ced age. It is very well known that the general population
is becoming older and that cardiovascular mortality and
morbidity increase with age. Therefore, it is very impor-
tant to identify all risk factors in order to reduce mortal-
ity and morbidity of CHD in the entire population, espe-
cially in the elderly.
The effect of the ACE D allele had been discussed
within the context of CHD in early 1992, when Cambien
et al. first reported an association of ACE DD genotype
with MI survivors. Observation of patients at »low« risk
according to classical risk factors showed ACE DD geno-
type as an independent risk factor5. At that time Mattu
et al. reported an association of the ACE D allele with
CHD in low risk patients. However, the association was
not present when the BMI was taken into account17.
Since then, several other groups have investigated the
possible relationship of ACE polymorphism with CHD. A
recent review that applied meta-analysis in examining
the cause-and-effect relationship between ACE ID poly-
morphism and cardiovascular renal risk could not identify
a significant association with hypertension but suggested
its role as a marker of atherosclerosis, cardiovascular
complications and diabetic nephropathy. Most of them
showed that DD genotype was a very strong risk factor
for coronary events (MI, fatal MI, and sudden death)5,6,10,18.
Numerous studies showed how DD genotype was associ-
ated with increased risk for hypertension19–26, and could
be a significant risk factor and predictor for the develop-
ment of malignant hypertension25,27.
This study was dedicated to individuals of an ad-
vanced age. Using the univariate method, statistically
significant correlation between ACE D allele and CHD
was not determined for the entire group, or when males
and females were analysed separately. Distribution of
ACE gene polymorphism was in favour of ID genotype.
One possible explanation for the low level of DD at this
age is that ACE DD is not associated with longevity, and
ACE genotype proportion in senior subjects was different
from that in young and middle-aged subjects. Therefore,
subjects with DD genotype die or suffer MI at an early
age. On the other hand, some studies have failed to show
any correlation between the DD genotype and CHD. A
large prospective American physician’s study showed no
association between ACE ID polymorphism and the prev-
alence of MI or ischemic heart disease28. Some other
studies could not confirm any associations between ACE
ID polymorphism and CHD either. Only a few age-re-
lated studies have been conducted. Some of them confirm
the relation between the renin-angiotensin system and
systolic and diastolic blood pressure in the elderly. The
difference between the studies may partially be explain-
ed by the differences in sensitivity of the methods used to
assess association with CHD. Our study shows that, ac-
cording to qualitative analysis, deletion polymorphism of
ACE gene had no influence on the occurrence of CHD in
the elderly. However, multifactorial quantitative analysis
showed statistical significance. These results suggest that
the D allele of the ACE gene is a risk factor for CHD, also
in the elderly, but not at the conventional level of signifi-
cance. The slight significance at this age might be ex-
plained as a possibility that DD genotype is not associ-
ated with longevity and that the presence of »protective«
allele in a qualitative study might be affecting survival.
ACE plays a major role in the cardiovascular system
and is involved in the metabolism of two important
vasoactive peptides, angiotensin and bradykinin, which
are involved in the modulation of vascular tone and proli-
feration of smooth muscle cells. Subjects with DD genotype
appear to have a higher ACE level17, which is responsible
for increased angiotensin II levels and subsequently for
vasoconstriction. In the study, we also examined the in-
fluence of ACE DD genotype on ACE plasma activities.
As many other studies28, we showed a significant correla-
tion between ACE polymorphism and ACE plasma activi-
ties for the entire group and for females when observed
separately. Subjects with DD genotype appear to have the
highest ACE activity. This is in accordance with the re-
sults obtained in the study by Rigat et al.3. We also con-
firmed that the ACE plasma activity was stable and re-
lated to ACE polymorphism.
Conclusion
We proved that DD genotype was, however slight,
nevertheless a risk factor for CHD in the elderly. Strong
correlation between ACE polymorphism and ACE plas-
ma activities was demonstrated. A possible reason for
such weak linkage between DD genotype and CHD is
that ACE DD is not associated with longevity, or with fre-
quently present asymptomatic disease. A more likely and
more reasonable explanation could be that life style and
environment change the influence of the genetic marker.
We did not examine the influence of other diseases often
associated with MI. Other limitations underlying this
study were also present. A possible synergistic interac-
tion of the ACE gene polymorphism with other genes, as
well as an interaction between ACE ID polymorphism
and conventional risk factor, cannot be excluded.
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POLIMORFIZAM ACE GENA U PACIJENATA STARIJE @IVOTNE DOBI SA KORONARNOM
BOLESTI
S A @ E T A K
Povezanost delecijskog alela (DD genotip) angiotenzin konvertiraju}eg enzima (ACE) sa koronarnom bolesti srca
(KBS) je dvojbena. Malo je studija posve}eno tom problemu za stariju `ivotnu dob, ~iji rezultati su tako|er dvojbeni. Cilj
ovog rada je bio procijeniti povezanosti genetskih markera i rizika za KBS u starosti. Rezultati pokazuju da DD genotip
ima prediktivnu vrijednost za KBS u starosti prikazano diskriminacijskom analizom (c2=25,77; df=16; P=0.0620).
Me|utim upotrebljavaju}i univarijatnu metodu povezanost DD genotipa i KBS nije dokazana. Vrijednost aktivnosti
plazmatskog ACE u direktnoj je povezanosti s delecijskim polimorfizmom ACE gena. Zaklju~ak: Povezanost DD ge-
notipa i rizika za KBS u starijoj `ivotnoj dobi tako|er postoji. Prikazana je jaka povezanost ACE polimorfizma i vri-
jednosti aktivnosti plazmatskog ACE.
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